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The first candidates from the promising class of small non-antibody protein scaffolds are now moving
into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored
toward applications where they provide real advantages over established therapeutics to succeed in a
rapidly evolving drug development landscape.Introduction
Monoclonal antibodies represent a well-validated and rapidly
growing class of human therapeutics, characterized by a fully
human nature, long serum half-life, bivalency and immune effec-
tor functions [1,2]. Despite their successes, monoclonal antibodies
nevertheless face a range of restrictions that limit their applicabil-
ity. Many of these restrictions relate to the size of the antibody
molecule, which, in the case of the commonly used IgG isotype, is
in the range of 150 kDa. Moreover, antibodies are complex multi-
domain proteins, consisting of two different chains (heavy and
light) and a total of six different domains (designated VH, VL, CH1,
CH2, CH3 and CL). Assembly of the antibody molecule and much
of its stability rely on the correct formation of disulfide linkages
and on post-translational glycosylation of the constant region [3].
In combination, these requirements complicate the expression of
human antibodies in general, and hinder the production in the
cytoplasm of bacteria in particular [4,5]. To overcome the size and
stability limitations of monoclonal antibodies, a large body of
work has focused on the generation of small non-antibody scaf-
folds for human therapy and imaging applications [6–8]. In this
review, we discuss challenges in translating such scaffolds intoCorresponding authors: Jermutus, L. (jermutusl@medimmune.com),
Christ, D. (d.christ@garvan.org.au)
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http://dx.doi.org/10.1016/j.drudis.2015.09.004 validated drugs, and provide updates on their use in clinical
development and practice.
Challenges in the development of non-antibody
scaffolds
Non-antibody scaffolds under active development broadly fall
into two structural classes, namely domain-sized compounds (at
6–20 kDa molecular weight) and constrained peptides (2–4 kDa)
(Fig. 1). Domain-sized scaffolds include Affibodies, Affilins, Antic-
alins, Atrimers, DARPins, FN3 scaffolds (e.g. Adnectins and Cen-
tyrins), Fynomers, Kunitz domains, Pronectins and OBodies,
whereas Avimers, bicyclic peptides and Cys-knots are peptide-
related. A large number of candidates derived from these scaffolds
are currently under academic, preclinical and clinical develop-
ment (Table 1) and have shown great potential in terms of affinity,
target neutralization and stability, see [7] for a comprehensive
review.
Despite the considerable promise of non-antibody scaffolds,
conversion of the many examples of such modalities into differ-
entiated drugs has been challenging. Although several candidates
have progressed into clinical studies, only a single non-antibody
scaffold, the Kunitz domain DX-88 (ecallantide; Dyax) has been
granted regulatory approval (Box 1), with no further approvals
since 2009. Notably, the development of several candidates, in-
cluding DX-890 and AMG-220, has been halted in recent yearsC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FIGURE 1
Structural features of non-antibody scaffolds. Non-antibody scaffolds under active development broadly fall into two classes, namely domain-sized compounds
(Affibodies, Affilins, Anticalins, Atrimers, DARPins, FN3 scaffolds, Fynomers, Kunitz domains and OBodies) and constrained peptides (Avimers, Bicyclic peptides and
Cys-knots). The former class averages around 6–20 kDa, with constrained peptides falling into a lower range of molecular weights at around 2–4 kDa. Illustrations
were generated using PyMOL, positions diversified in the scaffolds are highlighted in red, disulfides are highlighted in yellow.
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TABLE 1
Protein scaffolds under clinical and preclinical development
Scaffold Company Target protein Drug name Indications Status
Adnectins [44,76–79] Bristol-Myers Squibb PCSK9 BMS-962476 Hypercholesterolemia Phase I NCT01587365
VEGFR2 Angiocept Cancer Phase II NCT00851045
NCT00850577 NCT00562419
Myostatin BMS-986089 Cachexia Phase I NCT02145234
EGFR/IGF-1R n/a Cancer Preclinical
Affibodies
[10,45,50,80–84]
Affibody HER2 ABY-025 Cancer (PET imaging) Phase I, II NCT01858116
NCT01216033 NCT02095210
Complement protein C5 SOBI002 Inflammation Phase I NCT02083666
IL-17 ABY-035 Autoimmunity Preclinical
TNF/IL-6 (AffiMab) n/a Inflammation Preclinical
EGFR, IGF-1R, PDGFRb,
HER3, VEGFR2
n/a Cancer Preclinical
Affilins [85,86] Scil Proteins Fibronectin EDB
splice variant
n/a Cancer Preclinical
CTLA-4 PRS-010 Cancer Preclinical
VEGF-A PRS-050 (Angiocal) Cancer Phase I NCT01141257
Anticalins [87–92] Pieris Hepcidin PRS-080 Anaemia Phase I NCT02340572
IL-4Ra PRS-060 Asthma Preclinical
HGFR PRS-110 Cancer Preclinical
CD137/HER2 PRS-343 Cancer Preclinical
IL-23/IL-17 PRS-190 Autoimmunity Preclinical
Atrimers [93–95] Anaphore IL-23 ATX 3105 Inflammation Preclinical
DR4 n/a Cancer
Avimers [49,96] Avidia, Amgen IL-6 AMG220 Crohn’s disease Phase I NCT00353756
Bicyclic peptides
[97,98,100,101]
Bicycle Therapeutics Kallikrein uPA HER2 n/a Hereditary
angioedema Cancer
Preclinical
Centyrins [102] Janssen HGFR n/a Cancer Preclinical
IL-17 Autoimmunity
TNF-a Inflammation
Cys-knots [103] Medimmune NaV1.7 n/a Pain Preclinical
DARPins [104–107] Molecular
Partners, Allergan
VEGF-A MP0112
(Abicipar pegol)
Macular degeneration
Macular edema
Phase II, Phase III
NCT02462928 NCT02462486
NCT01397409 NCT02186119
NCT02181517
VEGF-A/PDGF-B MP0260 Macular degeneration Preclinical
VEGF/HGF MP0250 Cancer Phase I NCT02194426
HER2 MP0274 Cancer Preclinical
Fynomers [46,108] Covagen TNF/IL-17A (FynomAb) COVA322 Plaque psoriasis Phase I/II NCT02243787
HER2 (FynomAb) COVA208 Cancer Preclinical
Kunitz domains
[109–112]
Dyax Kallikrein DX-88 (Ecallantide) Hereditary angioedema Approved
Neutrophil elastase DX-890 (Depelstat) Acute respiratory
distress syndrome
Phase II NCT00455767
Plasmin DX-1000 Cancer Preclinical
Obodies [113] Obodies n/a n/a n/a Preclinical
Pronectins [114] Protelica VEGFR2, AXL tyrosine
kinase, TNF-a, FZD receptors
n/a Cancer, Autoimmunity Preclinical
Tn3 [60,64] Medimmune CD40L n/a Autoimmunity Preclinical
TRAILR2 Cancer
Abbreviations: CD40L, CD40 ligand; CTLA-4, cytotoxic T-lymphocyte antigen 4; DARPins, designed ankyrin repeat proteins; DR4, death receptor 4; ED-B, extra domain-B; EGFR, epidermal
growth factor receptor; FZD, frizzled; HER2, human epidermal growth factor receptor type 2; HER3, human epidermal growth factor receptor type 3; HGFR, hepatocyte growth factor
receptor; IGF-1R, insulin-like growth factor-1 receptor; IL-17A, interleukin-17A; IL-23, interleukin-23; IL-4Ra, interleukin-4 receptor alpha; IL-6, interleukin-6; PCSK9, proprotein convertase
subtilisin kexin 9; PDGF-B, platelet-derived growth factor B; PDGFRb, platelet-derived growth factor receptor b; PET, positron emission tomography; TNF, tumor necrosis factor; TRAILR2,
TNF-related apoptosis-inducing ligand receptor 2; uPA, human urokinase-type plasminogen activator; VEGF-A, vascular endothelial growth factor A; VEGFR2, vascular endothelial growth
factor receptor 2.
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BOX 1
Clinical development of non-antibody scaffolds
Over 50 different protein scaffolds have been reported [6–8]. However, the majority of these scaffolds has exclusively been used in academic
settings and only a subset is currently further developed commercially (Table 1). A single non-antibody scaffold has received approval by the
FDA, the Kunitz domain KalbitorW (ecallantide; Dyax), a plasma kallikrein inhibitor used for the treatment of hereditary angioedema [144,145].
Ecallantide was selected by phage display [146], inhibits kallikrein activity with picomolar affinity and displays a moderate half-life (t1/2 2 h)
in humans [140,145]. Phase III clinical trials demonstrated significant improvements of acute angioedema symptoms compared with placebo
and a favorable safety profile, resulting in the approval of ecallantide in 2009 [147]. Competitors of the drug include the plasma-derived
human C1-esterase inhibitors BerinertW (CSL-Behring) and CinryzeW (ViroPharma/Shire), as well as the bradykinin receptor antagonist
FirazyrW (Shire). In addition to ecallantide the Kunitz domain DX-890 (depelstat; Dyax), a neutrophil elastase inhibitor, has been assessed in
clinical trials of cystic fibrosis [148]. The high stability of this domain enables pulmonary delivery [149], with Phase IIa clinical studies in 2008
resulting in reduced levels of the proinflammatory cytokine interleukin (IL)-8 in patients [111]. No clinical updates of DX-890 development
have been reported in recent years.
Affibodies have been developed for imaging applications and allow the visualization of metastases in vivo using positron emission
tomography (PET) [121,150]. The phage display selected compounds display picomolar affinity against the human epidermal growth factor
receptor (HER2)-neu tumor antigen [151]. Owing to their particularly low molecular weight (6 kDa), the compounds are characterized by
rapid blood clearance and a favorable biodistribution for imaging applications, as indicated by increased tumor:organ accumulation ratio in
comparison with the anti-HER2 IgG monoclonal trastuzumab [19]. A second generation Affibody molecule ABY-025 (Affibody) is currently
being evaluated as an imaging agent in Phase I/II clinical trials [80]. More recently, an Affibody compound targeting the complement protein
C5 commenced Phase I clinical evaluation for the treatment of inflammatory conditions (Table 1).
Adnectin scaffoldsdirected against the vascularendothelial growth factor receptor (VEGFR)2 tumor antigen[152]havebeenreportedandare
currentlyunderclinicalinvestigation.BMS-844203(angiocept;Bristol-Myers-Squibb)wasselectedthroughmRNAdisplayandbindsitstargetwith
nanomolaraffinity,effectivelyinhibitingVEGFR2activationandangiogenesis[153].CT-322wasformulatedasafusiontopolyethyleneglycol(PEG),
increasinghydrodynamicradiusandhalf-life(4days),whilereducingrenalclearance[78,154].PhaseIdoseescalationstudiesinhumansrevealed
that thecompoundwaswell tolerated,withamaximumdoseof2 mg/kg.Several Phase II studiesare currentlyongoing, including treatmentof
recurringglioblastoma[78,155].AnotherAdnectin-basedcompound,BMS-962476,directedagainstthecholesterolregulatorPCSK9,iscurrently
underPhase I investigation for the treatmentof hypercholesterolemia [77,156].Preliminarydata fromthis trial revealedthat treatmentwaswell
toleratedanddisplayedhighefficacy,withfreePCSK9levels reducedbyat least90%inpatients receivingasingle0.3 mg/kgdose[157].Thelatest
AdnectintohaveenteredclinicaltrialsisBMS-986089,amyostatininhibitorforcachexiaandmusculardystrophyindications,currentlyundergoing
aPhase I dose-escalationstudy (Table1).
AMG220 (C326; Avidia/Amgen) is an Avimer targeting IL-6, a pleiotropic cytokine associated with inflammatory and autoimmune conditions
[158]. Selected by phage display, AMG220 displays bi-specificity to its interleukin target, as well as binding to the Fc domain of IgG (resulting
in reduced renal clearance and FcRn recycling; Fig. 3). The compound has subpicomolar affinity for IL-6 [49] and displays a moderate serum
half-life (30 h) [96]. Phase I clinical trials of AMG220 in Crohn’s disease revealed dose-dependent reduction in serum C-reactive protein, an
inflammation biomarker synthesized by hepatocytes in response to IL-6 [96]. Despite its apparent efficacy, Amgen has suspended the clinical
development of the compound [114,159,160].
Anticalins are among the more actively developed non-antibody scaffolds, with a high number of lead compounds under preclinical
development – directed against CTLA-4 [90], hepcidin [161], hepatocyte growth factor receptor (HGFR; MET) [89], IL-4Ra [162] and IL-23/IL-17
[163] (Table 1). PRS-050 (AngiocalW; Pieris), is an antiangiogenic Anticalin targeting VEGF-A currently undergoing Phase I clinical investigation.
The compound was selected by phage display, and displays picomolar affinity to the VEGF-A molecule, as well as to splice variants [164]. To
increase serum half-life (to 6 days) PRS-050 was coupled to PEG, and evaluated in a dose-escalating Phase I clinical trial in patients with
advanced solid tumors [126]. The compound was mostly tolerated up to a dose 10 mg/kg, with no formal maximum dose reached. Rare
occurrences of grade 3 and 4 adverse effects were observed in this trial, however most effects were classified as mild-to-moderate. PRS-050
treatment resulted in effective VEGF-A neutralization, as indicated by the absence of free antigen, and the detection of VEGF-A–PRS-050
complexes [88,126].
The ankyrin repeat protein (DARPin) MP0112 (Molecular Partners/Allergan) targeting retinal angiogenic disorders driven by VEGF-A is
currently being assessed in clinical studies. These disorders include age-related macular degeneration (wet AMD) and diabetic macular
edema (Table 1). MP0112 was selected by ribosome display and displays picomolar affinity for its target [137]. Phase I studies of
intravitreal injection into the human eye revealed an ocular half-life of 13 days, with no detectable compound levels in serum. A
single treatment dose resulted in undetectable levels of ocular VEGF-A for up to 4 weeks in all patients. Preliminary efficacy data
obtained from a limited number of patients indicated reduced edema and improved visual acuity [137]. A subsequent Phase I/II study
supported these observations and parallel studies on wet AMD showed favorable outcomes for this indication, including a dose-
dependent reduction of vascular leakage [106,165]. MP0112 (abicipar pegol) entered Phase III clinical trials in 2015 (Table 1). In addition
to MP0112, the bi-specific DARPin MP0250 targeting VEGF/HGF has recently commenced clinical evaluation for the treatment of solid
tumors [166].
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candidate varies, it is evident that, as scaffolds have evolved from
innovative binding moieties to potential drug candidates, addi-
tional requirements have emerged. For example, one such require-
ment is the ability to match, and preferably exceed, potencies that
can be achieved by monoclonal antibodies. The quest for differ-
entiation faces three major challenges, namely serum-half life,1274 www.drugdiscoverytoday.comtissue penetration and advances in monoclonal antibody technol-
ogy.
Serum half-life
Repeated passages in serum significantly increase the uptake of
therapeutic proteins into tissue and organs. This is exemplified by
human IgG monoclonals, which display long serum half-lives (up
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FIGURE 2
Serum half-life of scaffolds and monoclonal antibodies. Non-antibody scaffolds are rapidly removed from the bloodstream, through filtration by the slit diaphragm
of interdigitating podocyte pedicles. Monoclonal antibodies of the IgG isotype do not underlie renal filtration, as a result of their molecular weight of 150 kDa,
well above the renal filtration barrier (60 kDa).
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scaffolds are largely eliminated through the kidney after a single
pass (Fig. 2) [10]. The lack of intrinsic half-life extension immedi-
ately puts scaffolds at a disadvantage, by limiting their ability to
accumulate at a site of pharmacological action. Consequently,
most scaffold-based drug candidates require the use of protein
engineering or formulation to ensure continuous exposure after
dosing.
Protein engineering can be used in multiple ways to extend the
circulating half-life of therapeutic proteins. The first approach is
based on increasing size to minimize single-pass kidney filtration.
This requires an increase above a critical mass of or above 60 kDa
(renal filtration cut-off) and is generally achieved through genetic
fusion with a larger protein or alternatively through conjugation
with an organic polymer, such as polyethylene glycol (PEG). The
first approach involves genetic fusions with the Fc region of
human IgG, or alternatively with serum albumin (both of which
interact with FcRn). This strategy is based on exploiting the salvage
mechanism mediated by the neonatal Fc receptor (FcRn) expressed
on vascular endothelial cells (Fig. 3) [11]. FcRn prevents lysosomal
degradation, and recycling can be achieved through direct and
indirect strategies [12]. Indirect mechanisms that trigger salvage
through FcRn include the engineering of scaffolds to bind IgG or
albumin (rather than a direct genetic fusion to these molecules).
This approach requires binding to these two serum proteins in
ways that do not interfere with their respective FcRn interactions;
it could however allow the generation of overall smaller constructs
than genetic fusions to antibody Fc regions.
Many examples of scaffold half-life extension have been
reported, see [13] for a review. However, it is important to note
that the FcRn pathway displays limited efficacy for molecules witha molecular mass under the renal filtration cut-off, because clear-
ance after a single pass through the kidney tends to be the more
dominant mechanism [14]. Therefore, unless advanced formula-
tion or delivery technologies are used, the minimal size for a
parenterally administered and infrequently dosed biopharmaceu-
tical drug effectively is 60 kDa. Unfortunately, the very addition
of a ‘half-life solution’ could thereby limit or even eliminate one of
the key advantages of non-antibody scaffolds, namely their rela-
tively small size and low molecular weight (2–20 kDa). An increase
in mass could also reduce other advantageous properties of these
molecules, such as high soluble expression and stability (Box 2).
Scaffold-based molecules with long plasma half-lives thereby risk
resembling IgG-like molecules with overall limited differentiation.
Tissue penetration
It is well documented that a low-molecular-weight therapeutic, if
of sufficiently high affinity to the target, will distribute more
effectively into tissue (Fig. 3), and extensive clinical data, particu-
larly relating to drug penetration into solid tumors, has been
reported [15,16]. This is particularly the case for smaller scaffolds
in the 2–4 kDa range, which are expected to extravasate and
diffuse into tissue effectively [17]. Whereas tissue penetration is
a recognized and crucial factor in the design of novel oncology
treatments, it is also relevant for other indications, if significant
organ diffusion is required following parenteral administration.
Examples include targeting less-vascularized tissues and organs,
such as intestine, adipose tissue and muscle, as well as renal and
lung lumina where, in each case, antibody IgG penetration is
limited [18]. Owing to their relatively low molecular weight,
unmodified scaffolds (e.g. without half-life extension) display
relatively fast tissue penetration in comparison with human IgGwww.drugdiscoverytoday.com 1275
REVIEWS Drug Discovery Today  Volume 20, Number 10 October 2015
Monoclonal
Slow
IgG
Tissue
FcRn
recycling
scaffold
Non-antibody
Fast
Blood
Extravasation
Capillary lumen
Basement membrane
Vascular endothelium
RBC
RBC
RBC
RBC
Tissue penetration
Extravasation
Tissue penetration
Drug Discovery Today 
FIGURE 3
Tissue penetration of scaffolds and monoclonal antibodies. Non-antibody scaffolds are capable of high levels of tissue penetration, owing to fast extravasation
from the capillary lumen through the vascular endothelium and basement membrane. By contrast, monoclonal antibodies of the IgG isotype are characterized by
slow tissue penetration. Unlike unmodified scaffolds, monoclonal antibodies display long serum half-lives, as a result of reduced renal filtration and recycling by
FcRn present in the vascular endothelium [11]. Abbreviations: RBC, red blood cell; FcRn, neonatal Fc receptor.
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half-lives, this can be exploited to engineer compounds with
excellent signal:noise ratios in imaging applications (Box 3)
[22]. A successful example is the development of radiolabeled
Affibody molecules for the imaging of human epidermal growth
factor (HER2)-positive tumors [19].
However, for therapeutic applications, a general advantage of
non-antibody scaffolds is less apparent. Owing to their large
molecular weight of 150 kDa, human IgG antibodies were ini-
tially considered to be limited to targets accessible directly from
the vasculature [7]. However, more-recent clinical data showed
that if dosed highly enough monoclonal antibodies can distribute
effectively in less-vascularized tissue [18]. The limiting factor of
antibody therapy in respect to tissue penetration therefore does
not just relate to the molecular mass of the therapeutic molecule
but also to the therapeutic index (i.e. dose at which toxicities will
occur) and cost of manufacture (i.e. total dose per patient per year).
As long as dose-limiting toxicities occur at doses that are signifi-
cantly higher than those required for efficient tissue penetration
(typically 1–10 mg/kg for IgG), antibody therapeutics can effec-
tively access most tissues in the body. Indeed, owing to their
intrinsically high potency, selectivity and specificity, therapeutic
indexes of antibodies are often large, enabling high doses to be
used clinically that are safe and well tolerated. Notable exceptions
relate to the brain and central nervous system [23,24]. In these
areas, although high doses will still lead to relatively higher
uptake, total drug levels are likely to be too low for significant
pharmacological action [25].
In summary, the need for alternative, highly tissue penetrating
scaffolds only arises if toxicities occur at doses insufficient for1276 www.drugdiscoverytoday.comeffective IgG tissue penetration (as can be observed after conjuga-
tion with cytotoxic agents, see section below) or if the antibody
dose required increases costs of goods to a commercially unviable
level. It should also be noted that the total dose is influenced by
the amount of drug required for the desired pharmacology and the
frequency of administration. For instance, an unmodified scaffold
antagonist might be administered at one-tenth of the dose of an
equivalent IgG therapeutic, but will require daily instead of bi-
weekly or monthly dosing. Scaffolds, however, could offer advan-
tages for locally administered therapeutics (such as for intravitreal
injection for ocular diseases), owing to their lower molecular
weight and higher solubility, and for applications in which Fc-
mediated immune effector functions are unnecessary or undesir-
able (for instance the neutralization of soluble signaling factors).
Advances in monoclonal antibody technology
Human antibodies of the IgG isotype are characterized by long
serum half-lives in the range of days to weeks [9]. Antibody half-life
can be further increased to timescales of several months, provided
that there is low target-mediated clearance, by engineering the
interaction of the antibody Fc region with the FcRn receptor,
resulting in increased uptake and favorable dosing regimens
[26]. Protein engineering approaches have also allowed the gener-
ation of smaller human antibody reagents, thereby reducing the
size-advantage of non-antibody scaffolds. For instance, Fcabs (F-
star) eliminate the requirement for antibody variable domains,
and instead rely exclusively on the antibody Fc region, by engi-
neering novel antigen-binding sites into constant regions [27].
These antibody variants combine the size advantage of a scaffold
with the intrinsic antibody half-life extension mechanism
Drug Discovery Today  Volume 20, Number 10 October 2015
BOX 2
Differentiation among non-antibody scaffolds
The large number of non-antibody scaffolds under development, encompassing a wide range of protein architectures, raises the question of
differentiation, and whether certain scaffold types might be particularly suited to specific applications. In terms of architecture and molecular
weight, scaffolds fall into two classes (domain-sized and peptide-derived; at 6–20 kDa and 2–4 kDa, respectively). This difference in molecular
weight directly relates to differences in production, with peptide-related compounds having the additional advantage of being amenable to
manufacture by chemical synthesis [167,100]. By contrast, domain-sized scaffolds generally need to be expressed in bacteria, or alternatively
in CHO-, Pichia-pastoris- or HEK-293-based eukaryotic systems (Table I). Overall lower molecular weight compared with IgG therapeutics is
also considered to be of particular importance for imaging applications (Box 3) and could allow the targeting of otherwise cryptic epitopes
within protein clefts and other poorly accessible structural features [100,168,169].
When conducting comparative analyses it should be noted that many scaffolds are proprietary to biopharmaceutical companies and that
data access might be restricted. Moreover, published studies could well have been conducted using varying conditions and methodologies,
further complicating analyses. Nevertheless, it is evident that there appear to be more similarities than differences between the properties
of different scaffold types. This is perhaps not surprising considering similar driving forces faced by companies developing non-antibody
scaffolds as human therapeutics. For example, most of the parental scaffold proteins have relatively high melting transitions, such as a Tm of
>80 8C for Adnectins [170], 79 8C for Anticalins [171] and 70 8C for Fynomers [108] – up to 120 8C for the recently developed
Alphabodies [172] – and most are reported to be well expressed in bacteria. By contrast, relatively large variation of properties can be
observed among binders of a single scaffold type (Table I). For instance, large differences in melting temperatures have been reported,
depending on the actual sequence and antigen specificity of each selected binder. This behavior is probably caused by the small size of the
scaffolds, resulting in the effect that relatively minor sequence changes can induce profound changes of overall biophysical or
pharmacokinetic properties [173]. Owing to their smaller size (2–20 kDa), residues in non-antibody scaffolds could be involved in high
affinity binding, as well as important biophysical properties, such as thermodynamic or colloidal stability [174]. Recognition of different
molecular targets could therefore have direct impact on a wide range of scaffold characteristics, which is in marked contrast to human
antibody therapeutics of the IgG isotype (150 kDa). Although the effect of sequence variation could in principle be analyzed by
computational or high-throughput methods, further releases of preclinical and clinical data will ultimately be necessary to evaluate
robustness and applicability of different scaffold types.
TABLE I
Biophysical and pharmacokinetic properties of non-antibody scaffolds.
Scaffold Expression Stability Half-life (in vivo)
Adnectins Escherichia coli 20–40 mg/l [115] Tm parent = 84 8C [116]
Tm selected = 37–73 8C [115,117]
>53 h (PEG) [78]
Affibodies Peptide synthesis [118] E. coli [119] Tm parent = 75 8C [120]
Tm = 42–71 8C [118]
4–14 min [121]
Affilins E. coli 100 mg/l [85] g-B-crystallin-based
Tm parent = 80 8C
Tm selected = 56–72 8C [85]
n/a
Ubiquitin-based
Tm parent = 82 8C
Tm selected = 54–66 8C [122]
20–56 h in mice (PEGylated,
Fc- or MSA-fused) [122]
Anticalins E. coli 2–20 mg/l [123] Tm parent = 79 8C
Tm selected = 53–73 8C [123–125]
6 d (PEG) [126]
Atrimers E. coli [127] Stable at 70–80 8C [95] 24 h (parental tetranectin)[95]
Avimers E. coli  1.4 g/l [49] No aggregation after 2 weeks at 50 8C [49] 30 h (Fc binding domain)[96]
Bicyclic peptides Peptide synthesis [100]
HEK-293 80 mg/l [128]
n/a 30 min in mice [129]
>24 h in mice (ABP- or Fc-fused)
[128,129]
Centyrins E. coli Tm parent = 93 8C
Tm selected = 46–87 8C [102]
n/a
Cys-knots E. coli 5–20 mg/l [130,131]
Peptide synthesis [132]
Tm > 100 8C [133,134] <35 min in mice [135]
DARPins E. coli
Up to 200 mg/l [136]
Tm > 66–89 8C [35,136]  13 d (PEG, ocular half-life) [137]
3 min in mice [20]
Fynomers E. coli 24–78 mg/l [138]
CHO 3.5–20.7 mg/l [46,139]
Tm parent = 70 8C [139] 68 h in mice (Fc-fused) [139]
Kunitz domains Pichia pastoris [140] 75% active after heating to 95 8C [140,141] 2 h [142]
OBodies E. coli 100–200 mg/l [113] Tm = 66–81 8C [113] n/a
Tn3 E. coli 40–400 mg/l [60] Tm = 83 8C [143] 36 min in mice [60]
Abbreviations: ABP, albumin-binding peptide; CHO, Chinese hamster ovary cells; Fc, fragment crystallizable; HEK, human embryonic kidney cells; MSA, mouse serum albumin; PEG,
polyethylene glycol; Tm: melting temperature.
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BOX 3
Imaging applications of non-antibody scaffolds
Non-antibody protein scaffolds (including Affibodies, Bicyclic peptides, Cys-knots, DARPins, Anticalins and Adnectins) have been successfully
conjugated to radionuclides and near-infrared (NIR) fluorescent dyes for in vivo imaging of solid tumors, reviewed in [175]. These reagents
with affinities down to the nanomolar to picomolar range have several biophysical properties that make them ideal candidates for molecular
imaging in preclinical and clinical studies. Important properties that distinguish them from antibody-based reagents are the absence of the
immunoglobulin Fc region and an overall small size (2–20 kDa), enabling efficient capillary extravasation and tissue diffusion (Fig. 3). This
behavior is particularly relevant to diagnostic applications in oncology [176,177]. In addition, unmodified scaffolds that do not include
antibody Fc regions or bind to IgG or albumin, display short serum half-life and are rapidly cleared from the body (Fig. 2). Such protein
scaffolds offer the potential of increased signal:noise ratios in comparison to antibody-based imaging reagents. This is exemplified by the
iodinated ABY-002 Affibody molecule, which displays excellent bioavailability and image contrast when benchmarked against the anti-HER2
monoclonal antibody trastuzumab (HerceptinW; Genentech) [19].
More recently, multiple studies have provided insights into the biophysical characteristics that maximize tumor uptake and minimize off-
target effects. In addition to low molecular weight as a key determinant of vascular permeability and tissue accessibility [177,178], these
studies have also revealed other effects that influence the retention of the label in the tumor. These include affinity and avidity of the
scaffold, as demonstrated for DARPins [20] and Affibodies [151], and whether it is internalized and degraded [179]. In addition, overall
hydrophilicity has been shown to determine whether the scaffold is retained in off-target sites such as the liver or the kidneys. This has been
demonstrated for Adnectins, which are relatively hydrophilic and have been shown to have longer renal than hepatic retention [180].
Similarly, removal of electric charges from Cys-knots [181] and Adnectins [180] has been shown to reduce renal retention. Importantly,
chelators used to conjugate protein scaffolds to radionuclides for positron emission tomography (PET), single-photon emission computed
tomography (SPECT) and scintigraphic imaging, and NIR dyes for optical imaging have the potential to alter size, affinity and charge. For
example, the substitution of a positively charged lysine residue with the neutral serine has been shown to decrease renal retention of an
Affibody molecule [182].
An innovative concept, originally developed to improve the delivery of therapeutic payloads and imaging reagents by monoclonal
antibodies, is the use of pre-targeting with a bi-specific molecule [183]. The approach involves the use of bi-specifics recognizing tumor
antigen and a small ligand, which can be administered at a later stage after the antibody has been cleared from the circulation and from off-
target sites. This ligand can serve as a vehicle for payload delivery for therapeutic or imaging applications. Examples include an Anticalin
domain specific for fluorescein fused to an antibody specific for a tumor antigen. This pre-targeting strategy has enabled sensitive in vivo
imaging of tumors using a fluorescein–NIR-dye conjugate [184].
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tumor uptake per injected dose by combining the advantages of
small size and long circulating half-life [27,28]. The clinical evalu-
ation of an anti-HER2 FcabTM (NCT02286219) will determine
whether these favorable pharmacokinetic properties are translat-
able into humans.
Although non-antibody scaffolds often display high thermody-
namic stabilities, it is evident that the stability of human antibody
reagents can be increased through well-established protein engi-
neering approaches [3]. A generally low propensity to aggregate is
another desirable property of non-antibody scaffolds; however,
methods for increasing the aggregation resistance of human anti-
body reagents are increasingly becoming available [3,29–31]. Fi-
nally, the cost of production of non-antibody scaffolds is
potentially lower, because of the possibility of using bacterial
rather than mammalian expression systems [32,33]. However,
with a large number of antibody therapeutics transitioned into
commercial production and increased economies of scale, the cost
of goods for CHO-cell-expressed antibody IgG therapeutics is
decreasing, and can often be adequately controlled through effi-
cient chemistry, manufacturing and control (CMC) processes [32].
Strategies for the generation of differentiated non-
antibody scaffold drugs
To overcome challenges associated with serum half-life, tissue
penetration and advances in monoclonal antibody technology,
a wide range of protein engineering and drug delivery approaches
have been applied to non-antibody scaffolds. Here, we discuss
current advances and propose further areas of innovation.1278 www.drugdiscoverytoday.comFormulation and novel delivery devices
Owing to the problems associated with half-life extension the use
of slow-release formulations and innovative drug delivery, devices
could become an attractive strategy for non-antibody scaffolds.
Provided the required efficacious total dose is sufficiently low (in
terms of mg), both approaches can enable high serum concentra-
tion, despite the use of drug candidates with intrinsically short
serum half-life. Slow release formulation has a long track record in
the administration of agonistic peptides (including Zoladex1 and
Bydureon1), but has not been extensively applied to non-anti-
body scaffolds [34]. This is because of the antagonistic pharmacol-
ogy of most scaffold-based drug candidates, which generally
require relatively high doses to neutralize a significant proportion
of the target molecule stoichiometrically. Such doses had been
considered too high to be formulated successfully through a slow-
release approach. However, with recent reports of scaffolds engi-
neered to reach antibody-like affinities in the picomolar [35] to
femtomolar [36] range, such limitations might no longer apply for
next-generation candidates. With the typical molecular weight of
a non-antibody scaffold at one-tenth of an IgG monoclonal (as-
suming unmodified scaffolds), doses of up to 10 mg per adminis-
tration could thereby become feasible, which are accessible
through slow-release formulation. Alternatively, innovative drug
delivery devices, such as mini-pumps, are increasingly becoming
available. Such devices were pioneered in the treatment of diabetes
patients, and are currently in late-stage clinical testing [37]. Exam-
ples include exenatide, a short-half-life glucagon-like peptide
(GLP-1) receptor agonist, administered through up to yearly dos-
ing. Significant opportunities exist through the use of such devices
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BOX 4
Immunogenicity of non-antibody scaffolds
Immune responses to administered protein therapeutics remain a
significant challenge for clinical success. For non-antibody scaffolds
immunogenicity can represent a greater challenge than for
antibodies, particularly for those derived from non-human or
synthetic proteins. An innovative approach relates to the recent
development of scaffolds chemically synthesized with D-amino
acids (Reflexion Pharmaceuticals) [185]. These compounds are
mirror images of their parental protein G B1-domains and are
expected to be structurally nonimmunogenic [186].
To date, there have been few reported clinical trials of non-
antibody scaffolds. KalbitorW (ecallantide; Dyax), currently the only
non-antibody scaffold protein therapeutic approved by the FDA,
has undergone extensive clinical trials for the treatment of
hereditary angioedema [187,188]. In 216 patients treated with
ecallantide, 36 (17%) developed anti-drug antibodies, along with
several reported cases of patients developing antibodies to Pichia
pastoris, the organism used to manufacture the drug. BMS-844203
(angiocept; Bristol-Myers-Squibb), an Adnectin targeting vascular
endothelial growth factor receptor (VEGFR)2 has been assessed at
escalating intravenous doses in patients with advanced solid
tumors [78]. This study reported anti-drug antibodies in 31 of 38
(82%) patients. Subsequent epitopic analysis revealed that the anti-
drug antibodies bound to the engineered binding loops of the
Adnectin. A Phase I study of PRS-050 (AngiocalW; Pieris), an
Anticalin targeting VEGF-A, in 25 patients with advanced solid
tumors also reported no anti-drug antibody responses in any of the
patients [126].
It remains difficult to draw general conclusions from what is so far
a small number of clinical studies, in terms of predicting
immunogenicity and the effects on safety and efficacy. Moreover,
immunogenicity is a complex phenomenon that is known to be
influenced by factors outside of the molecular structure of the
therapeutic (including dosing, formulation, excipients, the
presence of contaminants such as host cell proteins or degradation
products, the route of administration, and the immune and genetic
status of the patient) [189]. Although preclinical assessment of
immunogenicity risk can be conducted using in silico or in vitro
prediction methods or by in vivo assessment of anti-drug
responses in rodents or non-human primates [190], clinical data
required to determine relative utility in predicting anti-drug
responses in patients is not yet publically available. Further clinical
studies of non-antibody scaffold therapeutics will ultimately be
required to address the relative immunogenicity of different
scaffolds classes.
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candidates. This area has remained largely unexplored, however it
might well see increasing interest as companies try to find new
ways to generate candidates out of their often significant invest-
ment in scaffold technologies [38,39].
Multi-specificity
The concept of dual (or multiple) specificity has attracted consid-
erable attention in recent years [40–42]. Many approaches focus on
the concept of taking two or more validated biologics and com-
bining them in one construct. Such constructs have the ability to
target either multiple proteins or multiple epitopes on the same
molecule simultaneously [43] and several examples of scaffold-
based constructs have been reported (including DARPins, Antic-
alins, Affibodies, Adnectins and Fynomers) [44–50]. The latter
strategy can potentially lead to enhanced neutralization efficacy
[51] or to increased clearance through the induction of large
immune complexes [52]. Although considerable advances have
been made in the design and manufacture of antibody-based bi- or
multi-specifics, challenges remain. In particular, accurate predic-
tion of the resulting combined pharmacology and the accurate
adaptation of each pharmacological activity to result in a potent
but nontoxic molecule at, effectively, a fixed dose have turned out
to be more complex than first anticipated. Furthermore, a multi-
selective biologic might require multiple biomarkers to assess the
therapeutic window accurately for each pharmacological moiety,
resulting in a significant increase in development costs – discussed
in further detail, in particular in comparison to polyclonal anti-
body approaches, in a recent review on bi-specifics [53]. Conse-
quently, a majority of the limited number of non-cell-crosslinking,
bi-specific antibodies progressing to pivotal Phase IIb studies target
highly related biological pathways, thereby simplifying the trans-
lational medicine and safety strategy. Examples include antibodies
against IL-4/IL-13 (Sanofi) [54], Her1/Her3 (Genentech/Roche)
[55] or Her2/Her3 (Merrimack Pharmaceuticals) [56]. However,
the targeting of related pathways could also ultimately limit the
differentiation of the resulting bi-specific versus the mono-specific
parental antibodies or, indeed, combinations of the parental anti-
bodies.
The remaining technical complexities of generating multi-spe-
cific antibody therapeutics open up possibilities for the develop-
ment of non-antibody scaffolds, either on their own or as an ‘add-
on’ to antibody therapeutics [51,50]. Indeed, multimerization
plays to the advantage of scaffold platforms, which provide highly
soluble, stable and well-expressing monomer building blocks for
such strategies. Moreover, a potentially unique feature of scaffold
multimerization is the ability to generate potent agonists, which
can be readily achieved for targets that can be activated through
simple di- or tri-merisation. Examples for this behavior include the
tumor necrosis factor (TNF) family of receptors [57] and many G-
protein-coupled receptors (GPCRs) [58]. The approach is exempli-
fied by the targeting of TRAIL-R2 (also known as death receptor 5,
DR5) with several candidates under preclinical [59,60] and clinical
[61] development. Multimerization has also been described as a
pragmatic way to boost the potency of the often more weakly
binding monomer [62,63]. Scaffold multimerization is not with-
out challenges, for instance repeating identical epitopes within a
molecule can trigger innate immunity [64]. Protein multimeriza-tion can also initiate aggregation processes, which increase the
immunogenic potential (Box 4) [64,65]. However, the high intrin-
sic stability of non-antibody scaffolds is likely to limit such pro-
cesses [7].
Drug conjugates
Although nonmodified IgG antibodies typically show toxicities
only at super-pharmacological doses, they are more common for
antibody–drug conjugates (ADCs) at even moderate dose levels
[66]. These toxicities can be dose-limiting in the clinic, and in turn
limit the penetration of the ADC into solid tumors (this is in
contrast to liquid tumors where malignant cells are mostly acces-
sible in serum and generally less affected by dose restrictions) [59].
Scaffolds have the potential to offer significant advantages in such
a scenario, by delivering a toxic moiety deep into a solid tumor
mass while being rapidly cleared from systemic circulation. Earlywww.drugdiscoverytoday.com 1279
REVIEWS Drug Discovery Today  Volume 20, Number 10 October 2015
R
eview
s
P
O
S
T
S
C
R
E
E
NADC designs were based on human antibody fragments. Examples
include moxetumomab pasudotox (Medimmune/AstraZeneca), a
CD22-targeting antibody fragment fused to a shortened Pseudo-
monas exotoxin, which has now reached Phase III trials [67].
Furthermore, antibody-based ADCs can suffer from aggregation
owing to the hydrophobicity of the attached chemical payload
[68,69]. Stable and nonaggregating scaffolds can therefore provide
an attractive alternative in such situations, in particular if an
overall small molecular weight compatible with high tumor up-
take can be maintained [17,70] and a wider range of conjugation
chemistries can be explored compared to working with IgG anti-
bodies [71]. A number of reports demonstrate that scaffolds, in
particular constrained peptides, unmodified and as conjugates to
radionuclides, are highly metabolically stable [72,73] and were
shown to be secreted intact in the urine [74]. This high metabolic
stability is achieved by working with fully synthetic molecules
where a stable and highly inert linkage between the scaffold
peptide and the conjugate can be easily selected.
Concluding remarks
Over the past decade, a large number of pharmaceutical companies
have invested significantly in either acquiring or building in-house1280 www.drugdiscoverytoday.comscaffold technologies. The first generation of such non-antibody
drug candidates is now progressing into clinical trials. However,
challenges remain, and the wider translation of scaffold drugs
into clinical practice will require additional innovation. Al-
though a handful of promising and differentiated scaffold drug
candidates continue to advance clinically, it could be their use as
drug conjugates, or the combination with advanced formulation
and delivery technology, that will ultimately drive value crea-
tion. Considering that the expenditure of developing over 50
scaffold technologies will have to be recovered, this will require
considerable time and the development of new and differentiat-
ed therapeutic leads. Scaffold-based platforms could also allow
the development of fast and efficient diagnostics, resulting in a
reduced cost of clinical imaging, an application with significant
promise. Disruptive innovation could also result from further
reducing the molecular size of the scaffolds down to the propor-
tions of macrocycle drugs [75]. This could open up new and
exciting opportunities, including the targeting of intracellular
interactions and oral administration. In summary, further crea-
tivity will be required to transform this promising class of
binding molecules into validated therapeutic and diagnostic
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